- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.09. | How J&J paved the way for Compass' coming psychedelic drug launch | ||
| 21.09. | Are healthcare systems really ready for GLP-1s? | ||
| 21.09. | Behind the outcomes: How whole-patient support is reshaping oncology care | ||
| 18.09. | Xenon shares fall following depression trial pause | ||
| 18.09. | This week in charts: GSK's China deals, the $300M IPO club and selling the news | ||
| 18.09. | Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug | ||
| 18.09. | Electra Therapeutics amasses $350M in biotech's latest big IPO | ||
| 17.09. | Novo partners with Orbis, deepening investment in oral peptide drugs | ||
| 17.09. | North Immunology joins biotech reverse merger boom with Aethlon deal | ||
| 17.09. | Roche, Dualitas team up to find bispecific drugs for immune diseases | ||
| 16.09. | Novartis to pay $125M for blood-brain barrier crossing platform | ||
| 16.09. | Novo looks to Anthropic's AI models to 'supercharge' drug development | ||
| 16.09. | Sling banks $123M for an experimental thyroid eye disease pill | ||
| 15.09. | FDA clears first generic radioligand drug; Sionna turns to layoffs | ||
| 15.09. | WCLC '26: A new 'ADC era,' China questions and AstraZeneca's spotlight | ||
| 15.09. | FDA launches pilot program to speed up early US drug research | ||
| 14.09. | Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results | ||
| 14.09. | AstraZeneca's newly approved pill fails frontline breast cancer study | ||
| 14.09. | Cellectis quits CAR-T and pivots to 'in vivo' gene editing | ||
| 14.09. | Scholar Rock SMA drug approved by FDA | ||
| 11.09. | This week in charts: RA's insatiable appetite, Novartis' big slide and a reverse merger spree | ||
| 11.09. | Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use | ||
| 11.09. | mRNA cancer vaccines' biggest barriers to market | ||
| 10.09. | FDA places partial hold on Biohaven's epilepsy drug | ||
| 10.09. | Andy Plump, architect of Takeda's R&D overhaul, to retire next year |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.